Three ASX companies jockeying to be the next biotech winners
Clarity Pharmaceuticals reports it eliminated prostate cancer in a patient; LTR Pharma wants to sell nasal viagra; and Opthea has clinical trial results soon.
To make blockbuster returns in the sharemarket, you’ve got to find the winners of tomorrow, not today.
It’s easier said than done, but not impossible. As shareholders in Neuren Pharmaceuticals, Pro Medicus or Telix Pharma will tell you after watching the value of their shareholdings rocket between 10 and 100-fold over a few years.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
